Home > Riviste > Minerva Biotechnology and Biomolecular Research > Fascicoli precedenti > Minerva Biotecnologica 2015 December;27(4) > Minerva Biotecnologica 2015 December;27(4):219-23

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi
Per citare questo articolo
Share

 

REVIEWS   

Minerva Biotecnologica 2015 December;27(4):219-23

Copyright © 2015 EDIZIONI MINERVA MEDICA

lingua: Inglese

SIGIRR/TIR8: a potential therapeutic target for inflammation treatment

Tejeda Gómez Y. 1, Pentón Rol G. 2, Fernández Massó J. R. 1

1 Pharmacogenomics Division, Center for Genetic Engineering and Biotechnology, Havana, Cuba; 2 Clinical Trials Division, Center for Genetic Engineering and Biotechnology, Havana, Cuba


PDF


Inflammation is a fundamental response to tissue injury and invasion of pathogens, but it is detrimental in clinically important inflammatory disorders. Despite the extended use of conventional anti-inflammatory drugs there is a need for new drugs and therapeutic targets to overcome the high risk disadvantages related to such use. SIGIRR/TIR8 is a phylogenetically conserved molecule which is widely expressed in the organism and plays a key role in innate immune response and T helper polarization. It regulates NF-kB pathway triggered by IL1R1 and TLRs. The ability to dampen signaling from ILRs and TLRs family members makes TIR8/SIGIRR a key regulator of inflammation. This review summarizes the most recent and outstanding evidences on SIGIRR/TIR8 expression and regulation which make this molecule a promising target for new drugs development in anti-inflammatory therapy against autoimmune diseases (e. g. systemic lupus erythematosus), rheumatoid arthritis, asthma, gut inflammation diseases and others.

inizio pagina